Patent · US Expired

Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells

US4695459A · kind A · utility

46Cited by

0References

7Claims

0Family size

Assignee

Board of Trustees of the Leland Stanford Junior University · US

Inventors

Lawrence Steinman · Stanford, US
Matthew K. Waldor · Brookline, US
Subramanian Sriram · Burlington, US
Leonard A. Herzenberg · Stanford, US
Leonore A. Herzenberg · Stanford, US

Key dates

Filing date	Dec 26, 1984
Grant date	Sep 22, 1987
Priority date	—
Expiry date	Dec 26, 2004

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY10S530/868
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

Certain autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus may be prevented or attenuated by in vivo treatment with a complement-fixing anti-Leu3 (CD4) antibody that is cytotoxic to Leu3 (CD4) phenotype T cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.